Abstract
18F-Fluoro-Deoxyglucose (FDG) Positron Emission Tomography (PET) is an imaging technique used to study glucose metabolism in cells. It is particularly useful in oncology, especially for initial diagnosis and the detection of recurrence. Thanks to its functional approach to tissues, its use has evolved towards the evaluation of anticancer treatments, both in a personalized approach to patients and as part of clinical trials of new biotherapies. This technique provides additional information compared to conventional imaging, which is not always able to assess tumor viability of potentially necrotic or fibrotic residual masses after treatment. However, the use of FDG-PET requires a rigorous methodology, both for the performance of the studies and for their interpretation. Based on a large body of literature, interpretation criteria for solid tumors have been published and updated. PERCIST 1.0 (Positron Emission Tomography Response Criteria In Solid Tumors), proposed by an American task force in 2009, aims to clarify and standardize practice. These criteria will evolve according to the specificities of new biotherapies such as immunotherapy.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
